At a Glance
- Company: Oracle Corporation
- Location: Global; platform built on Oracle Cloud Infrastructure
- Headline figures: New generative‑AI‑enabled platform (no standalone price disclosed)
- Focus area: AI‑powered analytics for pharma, medtech and research
- Next steps: Adoption by life sciences organisations; showcase at SCOPE 2026
What happened?
Oracle has launched the Oracle Life Sciences AI Data Platform, a generative‑AI‑enabled solution designed to unify and analyse large, heterogeneous datasets for pharmaceutical, medical device and research organisations. The platform integrates customers’ owned data with third‑party sources and more than 129 million de‑identified longitudinal electronic health record (EHR) records from Oracle Health Real‑World Data.
Why does it matter?
Fragmented, siloed data is a major bottleneck in drug discovery, trial design and post‑market surveillance. By bringing together internal, external and real‑world data in a single AI‑ready environment, the platform aims to accelerate hypothesis generation, reduce time‑to‑insight and support faster, evidence‑based decision‑making across R&D, clinical trials, pharmacovigilance and commercialisation.
Who’s behind it?
Oracle Health and Life Sciences developed the platform under the leadership of Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. It plugs into Oracle Cloud Infrastructure (OCI), the Oracle Life Sciences AI Application Suite, Oracle Fusion Cloud SCM and Fusion Cloud Sales, giving life sciences customers an integrated stack for data, analytics and operations.
How was it achieved?
The platform uses generative AI and “agentic” reasoning to surface insights from 129M+ de‑identified EHR records and other data sources. It offers out‑of‑the‑box AI agents and tools for users to build custom agents that can propose analyses, refine hypotheses, generate synthetic control arms, conduct health‑economics and outcomes research, and monitor safety signals—all while maintaining data‑lineage visibility and operating within user‑defined guardrails.
What’s next?
Oracle plans to drive adoption among pharma and medtech customers and will showcase the platform at SCOPE 2026 in Orlando, Florida. Life sciences organisations are expected to use it to streamline regulatory submissions, explore label‑expansion opportunities and scale research capacity without proportionally increasing headcount.
What are people saying?
Seema Verma said fragmented, inconsistent data “holds back life sciences organisations from delivering the medical breakthroughs that could transform and even save lives,” and positioned the platform as a way to “reveal deep insights that are often not possible with humans alone.”